Significance of <i>BRCA2</i> and <i>RB1</i> Co-loss in Aggressive Prostate Cancer Progression
Goutam Chakraborty(National Centre for Cell Science), Philip W. Kantoff(Dana-Farber Brigham Cancer Center), Joshua Armenia(Memorial Sloan Kettering Cancer Center), Kalyani Chadalavada(Memorial Sloan Kettering Cancer Center), Yuki Yoshikawa(Memorial Sloan Kettering Cancer Center), Gwo‐Shu Mary Lee(Dana-Farber Cancer Institute), Ying Z. Mazzu(Memorial Sloan Kettering Cancer Center), Gouri J. Nanjangud(Memorial Sloan Kettering Cancer Center), Lorelei A. Mucci(Harvard University), Konrad H. Stopsack(Memorial Sloan Kettering Cancer Center), Wassim Abida(Memorial Sloan Kettering Cancer Center), Kazumasa Komura(Osaka University of Pharmaceutical Sciences), Nabeela Khan(Memorial Sloan Kettering Cancer Center), Subhiksha Nandakumar(Memorial Sloan Kettering Cancer Center), Lina Jehane(Memorial Sloan Kettering Cancer Center), Rahim Hirani(New York Medical College), Yu Chen(Memorial Sloan Kettering Cancer Center), Mohammad Atiq(Memorial Sloan Kettering Cancer Center)
Cited by 114
Related Papers
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
|New England Journal of Medicine|2010|5.5k
Integrative Clinical Genomics of Advanced Prostate Cancer
|Cell|2015|3.6k
Gene expression correlates of clinical prostate cancer behavior
|Cancer Cell|2002|2.5k
Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3
|Journal of Clinical Oncology|2016|1.6k